Cancer therapies based on in vivo stimulation, or on adoptive T cell transfer of Vγ9Vδ2 T cells, have been tested in the past decades but have failed to provide consistent clinical efficacy. New, promising concepts such as γδ Chimeric Antigen Receptor (CAR) -T cells and γδ T-cell engagers are currently under preclinical evaluation. Since the impact of factors, such as the relatively low abundance of γδ T cells within tumor tissue is still under investigation, it remains to be shown whether these effector T cells can provide significant efficacy against solid tumors. Here, we highlight key learnings from the natural role of Vγ9Vδ2 T cells in the elimination of host cells bearing intracellular bacterial agents and we translate these into the setting of tumor therapy. We discuss the availability and relevance of preclinical models as well as currently available tools and knowledge from a drug development perspective. Finally, we compare advantages and disadvantages of existing therapeutic concepts and propose a role for Vγ9Vδ2 T cells in immune-oncology next to Cluster of Differentiation (CD) 3 activating therapies.Autophagy is a catabolic process involving vacuolar sequestration of intracellular components and their targeting to lysosomes for degradation, thus supporting nutrient recycling and energy regeneration. Accumulating evidence indicates that in addition to being a bulk, nonselective degradation mechanism, autophagy may selectively eliminate damaged mitochondria to promote mitochondrial turnover, a process termed "mitophagy". Mitophagy sequesters dysfunctional mitochondria via ubiquitination and cargo receptor recognition and has emerged as an important event in the regulation of liver physiology. Recent studies have shown that mitophagy may participate in the pathogenesis of various liver diseases, such as liver injury, liver steatosis/fatty liver disease, hepatocellular carcinoma, viral hepatitis, and hepatic fibrosis. This review summarizes the current knowledge on the molecular regulations and functions of mitophagy in liver physiology and the roles of mitophagy in the development of liver-related diseases. Furthermore, the therapeutic implications of targeting hepatic mitophagy to design a new strategy to cure liver diseases are discussed.Nanoindentation was utilized as a non-destructive technique to identify Portland Cement hydration phases. Artificial Intelligence (AI) and semi-supervised Machine Learning (ML) were used for knowledge gain on the effect of carbon nanotubes to nanomechanics in novel cement formulations. Data labelling is performed with unsupervised ML with k-means clustering. Supervised ML classification is used in order to predict the hydration products composition and 97.6% accuracy was achieved. Analysis included multiple nanoindentation raw data variables, and required less time to execute than conventional single component probability density analysis (PDA). Also, PDA was less informative than ML regarding information exchange and re-usability of input in design predictions. In principle, ML is the appropriate science for predictive modeling, such as cement phase identification and facilitates the acquisition of precise results. This study introduces unbiased structure-property relations with ML to monitor cement durability based on cement phases nanomechanics compared to PDA, which offers a solution based on local optima of a multidimensional space solution. Evaluation of nanomaterials inclusion in composite reinforcement using semi-supervised ML was proved feasible. This methodology is expected to contribute to design informatics due to the high prediction metrics, which holds promise for the transfer learning potential of these models for studying other novel cement formulations.This study was conducted on titanium diboride (TiB2) reinforced Al metal matrix composites (MMCs) with improved properties using a TiB2 and aluminum (Al) 1050 alloy. Al composites reinforced with fine TiB2 at volume ratios of more than 60% were successfully fabricated via the liquid pressing infiltration (LPI) process, which can be used to apply gas pressure at a high temperature. The microstructure of the TiB2-Al composite fabricated at 1000 °C with pressurization of 10 bar for 1 h showed that molten Al effectively infiltrated into the high volume-fraction TiB2 preform due to the improved wettability and external gas pressurization. In addition, the interface of TiB2 and Al not only had no cracks or pores but also had no brittle intermetallic compounds. In conclusion, TiB2-Al composite, which has a sound microstructure without defects, has improved mechanical properties, such as hardness and strength, due to effective load transfer from the Al matrix to the fine TiB2 reinforcement.Accounting for about 2% of cancers diagnosed worldwide, thyroid cancer has caused about 41,000 deaths in 2018. Despite significant progresses made in recent decades in the treatment of thyroid cancer, many resistances to current monotherapies are observed. In our complete review, we report all treatments that were tested in combination against thyroid cancer. Many preclinical studies investigating the effects of inhibitors of the MAPK and PI3K pathways highlighted the importance of mutations in such signaling pathways and their impacts on the subsequent efficacy of targeted therapies, thus reinforcing the need of more personalized therapeutic strategies. Our review also points out the multiple possibilities of combinatory strategies, particularly using therapies targeting proliferation, survival, angiogenesis, and in combination with conventional treatments such as chemotherapies. In any case, resistances to anticancer therapies always develop through the activation of alternative signaling pathways. Combinatory treatments aim to blockade such mechanisms, which are gradually decrypted, thus offering new perspectives for the future.  https://www.selleckchem.com/products/ga-017.html  The preclinical and clinical aspects of our review allow us to have a global opinion of the different therapeutic options currently evaluated in combination and to be aware about new perspectives of treatment of thyroid cancer.